Counting my change
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I am with you there....Have a great weekend
The following table includes registration statements and post-effective
amendments that were declared effective by the Securities and Exchange
Commission on the most recently completed business day.
The Securities Act of 1933 requires companies offering securities to file a
registration statement with the SEC that discloses material facts for
investors. The SEC staff reviews registration statements and declares them
"effective" if companies satisfy the disclosure rules.
REGISTRATIONS EFFECTIVE AS OF July 8, 2010
IPO:
GLOBAL CONDIMENTS, INC.
File Number: 333-164285
Date of Original Registration: 1/11/10
Form Type: S-1
Securities Registered: Minimum of 80,000 shares of common stock, and a
Maximum of 666,667 shares of common stock $0.75 per share
Selling Holder: No
STOCK:
AP PHARMA INC /DE/ (APPA)
File Number: 333-167890
Date of Original Registration: 6/30/10
Form Type: S-3
Securities Registered: 4,399,196 Shares of Common Stock
Selling Holder: Yes
HYDROGENICS CORP (HYGSD)
File Number: 333-167078
Date of Original Registration: 5/25/10
Form Type: F-3
Securities Registered: 200,000 Common Shares
Selling Holder: Yes
NOVELOS THERAPEUTICS, INC. (NVLT)
File Number: 333-166744
Date of Original Registration: 5/11/10
Form Type: S-1
Securities Registered: 60,000,000 Shares Common Stock
Selling Holder: No
S-4 s and F-4 s:
CENTRAL ILLINOIS PUBLIC SERVICE CO
File Number: 333-166095
Date of Original Registration: 4/15/10
Form Type: S-4
Securities Registered: 124,874 shares cumulative preferred stock
Selling Holder: No
Click here to go to Dow Jones NewsPlus, a web front page of today's most
important business and market news, analysis and commentary:
http://www.djnewsplus.com/nae/al?rnd=Sm80v8551YUiymkttVPw%2FQ%3D%3D. You can
use this link on the day this article is published and the following day.
(END) Dow Jones Newswires
07-09-10 0938ET
Copyright (c) 2010 Dow Jones & Company, Inc.
09:38 070910
LLBO News..Lifeline Biotechnologies Retains Legal Counsel to Resolve Trading Issue with
Depository Trust Services
RENO, Nev., Jul 09, 2010 (BUSINESS WIRE) -- Lifeline Biotechnologies, Inc. (Pink
Sheets: LLBO) announced today that it has retained legal counsel to resolve the
trading issue with Depository Trust Corporation (DTC) in order to re-establish
clearing services.
Jim Holmes, Lifeline's CEO, said, "We have retained special counsel to assist us
in re-establishing Depository Trust's services to our Company. The law firm we
have retained has been successful in re-establishing DTC's services to other
public companies who, the SEC alleges, were a part of the LEEB Brokerage
Services' questionable stock transactions, and is currently working with DTC's
outside legal counsel to remove the 'chill' that was placed on our stock in May."
Holmes reaffirmed, "We have no association or knowledge of LEEB, its
counterparts, representatives or their activities concerning the trading of
Lifeline's shares."
DTC is the clearing agency for public stock transactions. The broker-dealers
clear trades through DTC. Currently public stock trades transactions are cleared
through the DTC electronic system.
The Company remains focused, and its priority is the preparation and submission
of a First Warning System(TM) medical device 510(k) application and commensurate
commercialization.
Lifeline's website (http://www.lbti.com) has been comprehensively updated
providing extensive information on the company, its history and current affairs.
Safe Harbor: This release includes forward-looking statements within the meaning
of Section 27A of the Securities Act of 1933 and Section 27E of the Securities
Act of 1934. Statements contained in this release that are not historical facts
may be deemed to be forward-looking statements. Investors are cautioned that
forward-looking statements are inherently uncertain. Actual performance and
results may differ materially from that projected or suggested herein due to
certain risks and uncertainties including, without limitation, the ability to
obtain financing, successful development of the Company's product or market
acceptance of the product and regulatory and shareholder approval for anticipated
actions.
SOURCE: Lifeline Biotechnologies, Inc.
Lifeline Biotechnologies, Inc.
Jim Holmes, 775-326-9614
Jholmes@lbti.com
More TZPC News..ThermaFreeze(TM) Makes QVC Encore After Selling Out Initial Order in Six Minutes
Slotted to Appear on "Saturday Morning Q" at 10:30 AM ET This Saturday and "In
the Kitchen with David" at Noon on Sunday
RED BANK, NJ, Jul 08, 2010 (MARKETWIRE via COMTEX) -- ThermaFreeze(TM) Products
Corporation (PINKSHEETS: TZPC), the maker of patented refrigerant products
designed for consumer and commercial use, will make a special encore appearance
on QVC after selling out all of the initial units and back-ordering more during
its June 6 appearance on "In the Kitchen with David." The flexible, light dry gel
pack alternative to ice and ice substitutes will appear on "Saturday Morning Q"
this Saturday, July 10 at 10:30 AM ET and "In the Kitchen with David" this
Sunday, July 11 at noon ET.
In ThermaFreeze's previous appearance, QVC sold out all of its initial units and
back ordered an additional sum of units. For this weekend, the notable shopping
network placed an order for six times as many units as the initial order. A
single unit consists of 10 4x3cell pads and 5 6x4cell pads, with each cell
measuring 2.5'x2.5' and weighing about an ounce following hydration and
activation.
Utilizing a flexible design that contours to wrap around anything, ThermaFreeze's
plastic-and-cloth exterior helps the pack stay cold 75 percent longer than
traditional gel packs while providing easy size customization based on a
waffle-patterned design. Applications for ThermaFreeze reusable dry gel packs
range from treating injuries to packaging easy-spoil food items for shipping to
keeping a packed lunch cold.
One of the long-running network's most popular programs, "Saturday Morning Q"
features three hours of Saturday morning shopping with hosts and special guests.
From the things that help you take care of yourself (like beauty and personal
care items) to the things that help you take care of your home, whether you're
decorating, cleaning, repairing, organizing, cooking or upgrading with the latest
technology, Saturday Morning Q has just what you're looking for.
About ThermaFreeze(TM) Products Corporation ThermaFreeze(TM) Products Corporation
manufactures and markets a patented flat, lightweight and flexible dry gel pack
alternative to ice and ice substitutes designed for use in the commercial
shipment of perishables and as a consumer compress and chiller product. Featured
on QVC, ThermaFreeze is available for direct purchase by visiting Duane Reed,
Shoprite, Foodtown, King Kullen, Marsh Supermarket, Redner's and other select
stores. For more information, visit http://www.thermafreeze.com.
Safe Harbor for Forward-Looking Statements Statements made in this release with
the respect to the Company's current plans, estimates, strategies and beliefs and
other statements that are not historical are forward-looking statements.
Forward-looking statements include, but are not limited to, those statements
using words such as "believe," "expect," "plans," and words of similar meaning in
connection with a discussion of future operations, financial performance, events
or conditions. Statements are based on management's assumptions and beliefs in
light of the currently available information. The Company cautions that a number
of important risks and uncertainties could cause actual results to materially
differ from those discussed in the forward-looking statements and, therefore,
undue reliance should not be placed on them.
PRESS CONTACT:
Hanni Itah
SS|PR
(847) 415-9324
Email Contact
INVESTOR CONTACT:
ThermaFreeze Products Corporation
Joe Noel
(925) 922-2560
SOURCE: ThermaFreeze Products Corp
http://www2.marketwire.com/mw/emailprcntct?id=62A7838170AA66B1
Copyright 2010 Marketwire, Inc., All rights reserved.
Great News for POSC..Due to Demand Positron is Increasing Production of Attrius(TM) PET Scanners
INDIANAPOLIS, Jul 08, 2010 (BUSINESS WIRE) -- Positron Corporation (POSC), a
molecular imaging and solutions company specializing in Nuclear Cardiology and a
leader in Cardiac PET, announces that due to a greater demand for the Attrius(TM)
PET scanner, the Company has recently begun increasing production capacities with
its joint venture, Neusoft Positron Medical Systems.
Positron's award-winning, cardiac optimized PET scanner, the Attrius(TM), is the
only advanced, dedicated, cost-effective PET scanner in the marketplace. The
introduction of the Attrius(TM) last year has generated excitement throughout the
cardiac molecular imaging industry. Facilitated by the increase in reimbursement
for cardiac PET and an industry-wide movement to better and more efficient
medical imaging, Positron's Attrius(TM) has seen unprecedented interest and
sales. As a result of the recent sales, Positron has met its six month
projections and has to increase production earlier than previous estimations.
Based on Positron's current sales and a more robust pipeline, the Company
believes that they will surpass 2010 and 2011 targets of approximately 70 systems
in the next 18 months.
About Positron: Positron is a molecular imaging company focused on Nuclear
Cardiology. Positron utilizes its proprietary product line to provide unique
solutions to the Nuclear Medicine community ranging from imaging to
radiopharmaceutical distribution. Positron products include: the Attrius(TM), a
PET imaging device; the Pulse(R), a SPECT imaging device; the Nuclear
Pharm-Assist(R), an automated radiopharmaceutical distribution device; and the
Tech-Assist(TM), a radiopharmaceutical injection shield. More information about
Positron is available at http://www.positron.com.
Forward Looking Statements: Statements in this document contain certain
forward-looking statements within the meaning of Section 27A of the Securities
Act of 1933 and the Securities Exchange Act of 1934, as amended. These statements
are based on many assumptions and estimates and are not guarantees of future
performance and may involve known and unknown risks, uncertainties and other
factors which may cause the actual results, performance or achievements of
Positron Corporation to be materially different from future results, performance
or achievements expressed or implied by such forward-looking statements. Our
actual results may differ materially from the results anticipated in these
forward-looking statements due to a variety of factors, including, without
limitation those set forth as "Risk Factors" in our filings with the Securities
and Exchange Commission.
For further information please contact Positron Corporation at (317)576-0183.
AEMD Mentioned on Public radio and media...
Is It Easier For Some Athletes To Suffer Brain Damage?
by Frank Deford
July 7, 2010
Morning Edition
Cincinnati Bengals wide receiver Chris Henry died last year.
Enlarge Amy Sancetta/AP
Cincinnati Bengals wide receiver Chris Henry died on Dec. 17, 2009, from injuries he suffered after falling out of the back of a pickup truck. West Virginia University researchers say he suffered from chronic traumatic encephalopathy.
Cincinnati Bengals wide receiver Chris Henry died last year.
Amy Sancetta/AP
Cincinnati Bengals wide receiver Chris Henry died on Dec. 17, 2009, from injuries he suffered after falling out of the back of a pickup truck. West Virginia University researchers say he suffered from chronic traumatic encephalopathy.
text size A A A
July 7, 2010
An autopsy has shown that Chris Henry, the young Cincinnati Bengal who died a few months ago, suffered what is called CTE –– chronic traumatic encephalopathy –– which means, more simply, that his brain had been traumatized.
CTE can be diagnosed only in the brain tissue of cadavers, and 22 deceased former NFL players have been identified as having had it. Studies also show that elderly men who played football have four times the rate of dementia as do other U.S. males.
What makes the Henry case so frightening, however, is that he is the first current player to be diagnosed with CTE — and his case is even more of a tocsin because it doesn't seem that he suffered any serious concussions. How easy might it be for certain athletes to have their brains damaged?
Not just football players either. Studies by the American Academy of Pediatrics have shown that girls get concussions on the soccer field at much the same rate as boys do playing football. One cannot watch the World Cup, where players slug balls 60 sixty miles an hour with their heads — not to mention banging into opponents' heads — without thinking that the world's finest soccer athletes must surely be at the same risk of CTE as NFL players.
Jim Joyce was himself a football player. He got concussions of his own and also remembers laughing at befuddled teammates when they got, in the vernacular, "dinged." It was all a joke then, all part of being a tough guy on the gridiron.
Joyce's University of Maryland teammate, a stalwart, sensible guy named Tom McHale, made the NFL, but by the age of 45, diminished by depression and drugs, he had died of an overdose.
McHale's widow, Lisa, spoke hauntingly to a group of retired players recently about his tragic last years — he not knowing that his failures as a man were not really his, but were caused by the neurological distress that was surely the product of so many head hits on the football field.
Now Joyce, McHale's old friend, who is the chairman of Aethlon Medical, a research firm in San Diego, is conducting an investigation to discover whether there might be common biomarkers that could lead to identifying those with a predisposition to CTE.
Joyce suggests that if a test could be developed, it might help some parents steer their children away from sports like American football and soccer, where concussions are, sadly, just a part of the game.
"How does a father let his sons play football if he has been diagnosed with CTE?" Joyce asks.
Football and soccer are well established as, in the worst sense of the word, "head games." They're too popular to be substantively changed. But if we can find a way to discover which players are more susceptible to permanent damage from concussions, it will make both sports more tolerable entertainment.
I just cannot believe how under radar this company is...I found out that they already have orders for next year placed by some larger retailers.
TZPC News...HeadCoolie(TM) Adjustable, Reusable Head Wrap Provides Non-Chemical,
Non-Prescription Therapeutic Relief for Fever Symptoms and Headaches
HeadCoolie(TM) Stays Colder Longer; Perfect for a Hot Day Outdoors
BOSTON, MA, Jul 07, 2010 (MARKETWIRE via COMTEX) -- American Diversified Medical
Corporation, a majority owned subsidiary of ThermaFreeze Products Corporation
(PINKSHEETS: TZPC), today unveiled its newest product line, the HeadCoolie(TM).
HeadCoolie(TM) is a unique reusable adjustable headband designed to provide
children and adults, non-chemical, non-prescription therapeutic relief for fever
symptoms and headaches of all kinds, including migraines. HeadCoolie(TM) is used
to provide pain relief, but it's also great for keeping cool during hot summer
days, while playing sports or watching sports, for a day at the beach, during a
road trip, just before bedtime and more. HeadCoolie(TM) can be worn around the
head or on the back of the neck as needed.
Developed in the US by American Diversified Medical Corp. the HeadCoolie(TM) is
comprised of an adjustable neoprene headband with an internal pocket that holds a
proprietary lightweight, reusable insert that can be used hot or cold. The
HeadCoolie(TM) is insulated to retain heat or cold longer than a traditional hot
or cold pack and its adjustable strap and Velcro closure keep it comfortably in
place allowing the wearer to move about freely as they wear it. HeadCoolie(TM)
wraps comfortably around the wearers head and provides a soothing, consistent
pressure that gently compresses blood vessels to help relieve the discomfort and
pain of fevers and headaches, including migraines.
In a study published by the Archives of Family Medicine, head wraps like the
HeadCoolie(TM), that provide extracranial pressure coupled with heat or cold to
treat headaches were shown to alleviate migraine and tension headache pain in 87%
of patients. According to the National Headache Foundation, over 45 million
Americans suffer from chronic, recurring headaches and of these, 28 million
suffer from migraines. About 20% of children and adolescents also have
significant headaches.
"We are pleased and excited to offer this new relief option for the millions of
people that suffer tremendous pain and discomfort from chronic and often
debilitating headaches on a daily basis," said Holly A. Ruma, of American
Diversified Medical Corp. "For many generations placing a cold cloth on the
forehead has been a traditional home remedy and means of relieving the pain and
discomfort of fevers and headaches for both children and adults," said Ms. Ruma.
"The HeadCoolie(TM) takes the old concept of a cold cloth on your forehead and
brings it into the 21st century, by making it more comfortable, more convenient
and most importantly more effective than anything else available in the market."
Shipping and Availability
Available now, HeadCoolie(TM) can be purchased at pediatricians and physician's
offices across the country or directly through the company's consumer web site,
http://www.headcoolie.com.
Physicians interested in learning more about participating in the HeadCoolie
Medical Partner Program and can contact the company directly for more
information.
About American Diversified Medical Corporation American Diversified Medical Corp.
is a majority-owned subsidiary of ThermaFreeze Products Corporation. American
Diversified Medical Corp. is a diversified healthcare products and services
company with an emphasis on providing products and services into the alternate
site health care space, specifically, homecare and clinics outside the hospital
environment. It is American Diversified Medical Corp.'s intent to provide
products and services which will reduce the cost of providing healthcare and to
bring to market ways to avoid hospital admissions and the emergency room visits.
About ThermaFreeze Products Corporation ThermaFreeze(TM) Products Corporation
manufactures and markets a patented, innovative refrigerant product designed for
use in the commercial shipment of perishables and for use as a consumer compress
and chiller product. The ThermaFreeze refrigerant is flat, lightweight and
flexible, even when frozen, making it more convenient and cost-effective to use
than ice, gel packs, ice bricks and dry ice. For more information, visit
http://www.thermafreeze.com.
Safe Harbor for Forward-Looking Statements Statements made in this release with
the respect to the Company's current plans, estimates, strategies and beliefs and
other statements that are not historical are forward-looking statements.
Forward-looking statements include, but are not limited to, those statements
using words such as "believe," "expect," "plans," and words of similar meaning in
connection with a discussion of future operations, financial performance, events
or conditions. Statements are based on management's assumptions and beliefs in
light of the currently available information. The Company cautions that a number
of important risks and uncertainties could cause actual results to materially
differ from those discussed in the forward-looking statements and, therefore,
undue reliance should not be placed on them.
Contact:
Holly Ruma
American Diversified Medical Corp.
800-608-9457 ext.119
Email Contact
SOURCE: ThermaFreeze Products Corp
http://www2.marketwire.com/mw/emailprcntct?id=A938EA9F4B1D62B3
Copyright 2010 Marketwire, Inc., All rights reserved.
AEMD News..Aethlon Medical Announces Exosome Detection Assay
Assay to distinguish exosomes by their specific chemical structures -
SAN DIEGO, July 7, 2010 /PRNewswire via COMTEX/ -- Aethlon Medical, Inc. (AEMD),
the pioneer in developing therapeutic filtration devices to address infectious
disease and cancer, announced today that it has filed a provisional patent on
behalf of its wholly owned subsidiary Exosome Sciences, Inc. (ESI), relating to
the development of an assay that will allow researchers to detect exosomes in
blood and other fluids.
(Photo: http://photos.prnewswire.com/prnh/20090325/LA88762LOGO-b)
Beyond the potential therapeutic benefits of eliminating immunosuppressive
exosomes from circulation, researchers recognize that exosomes represent an
important diagnostic target to determine progression and prognosis of both
cancers and infectious disease conditions. However, the availability of
functional assays that specifically detect exosomes is limited. At present,
exosomes are generally characterized and purified by size chromatography and
general protein assay, not by chemical structures specific to the exosome. The
company's Enzyme Linked Lectin Specific Assay (ELLSA) is analogous to the well
established enzyme linked immunosorbent assay (ELISA), and has been designed to
bind specifically to carbohydrate structures common to exosomes, but not to
healthy human cellular components. Each ELLSA plate allows for up to 96 exosome
detection tests. Further analysis of the captured exosomes is possible through
detection molecules such as antibodies linked to a specific biomarker on the
exosome. "Our proprietary assay provides the potential for a previously
unrecognized revenue stream and further augments the relationships we have
established with thought leaders from the oncology field," stated Aethlon
Chairman and CEO, Jim Joyce.
About Aethlon Medical
At Aethlon Medical, we create revolutionary devices to address infectious disease
and cancer. Our devices are designed to be novel platform solutions that fill
therapeutic voids or aid in disease diagnosis and monitoring.
Our Hemopurifier(R) is the first medical device to selectively target the removal
of infectious viruses and immunosuppressive proteins from the entire circulatory
system. We recently discovered that our Hemopurifier(R) captures tumor-secreted
exosomes that suppress the immune system of those afflicted with cancer. Prior to
this discovery, a therapeutic strategy to directly inhibit or reverse the
immunosuppressive destruction caused by exosomes did not exist in cancer care. By
eliminating this mechanism, we believe our Hemopurifier(R) can fill an unmet
clinical need and provide the benefit of an immune-based therapy without adding
drug toxicity or interaction risks to established and emerging treatment
strategies.
Human studies have documented the ability of our Hemopurifier(R) to safely reduce
viral load in both Hepatitis-C virus (HCV) and Human Immunodeficiency Virus (HIV)
infected patients without the administration of antiviral drugs. However, our
initial clinical and commercialization focus is to establish our Hemopurifier(R)
as an adjunct therapy to enhance the benefit of both infectious disease and
cancer treatment regimens. In this regard, we plan to commercialize our
Hemopurifier(R) in India as we advance our clinical strategies in the United
States and the European Union. In vitro studies conducted by government and
non-government research institutes have also verified that our Hemopurifier(R)
has broad-spectrum capabilities against bioterror and emerging pandemic threats.
These studies have confirmed the capture of Dengue Hemorrhagic Virus, Ebola
Hemorrhagic Virus, Lassa Hemorrhagic Virus, West Nile Virus, H5N1 Avian Influenza
Virus, 2009 H1N1 Influenza Virus, the reconstructed Spanish Flu of 1918 Virus,
and Monkeypox Virus, which serves as a model for human Smallpox infection.
As a therapeutic device, the Hemopurifier(R) provides us with a pipeline into
four significant market opportunities:
Cancer: A treatment candidate to improve patient responsiveness to established
cancer therapies by removing immunosuppressive exosomes from circulation.
Hepatitis-C Virus (HCV): As an adjunct therapy to accelerate viral load reduction
at the outset of standard of care drug regimens.
Human Immunodeficiency Virus (HIV): Provides a potential therapeutic option for
HIV-infected individuals to manage disease progression once they become resistant
to antiviral drug regimens.
Bioterror and Pandemic Threats: Represents the most advanced broad-spectrum
strategy to address untreatable bioterror and emerging pandemic threats.
The Hemopurifier(R) is an expansive multi-patented platform technology whose
mechanism of action can be leveraged to provide therapeutic, diagnostic, and
biomarker discovery solutions. As a therapeutic, the Hemopurifier(R) is a
single-use disposable cartridge designed for implementation within the
established infrastructure of dialysis machines and other blood circulatory pumps
already located in hospitals and clinics worldwide.
In design, our Hemopurifier(R) is a selective filtration device containing
affinity agents that tightly bind to high-mannose structures unique to the
surface of exosomes produced by cancer and glycoproteins residing on the envelope
of viruses. These agents are immobilized around approximately 2800 porous hollow
fibers that run the interior length of our device. The resulting design provides
us the novel ability to separate both exosome and viral targets away from blood
cells so they can then be selectively and permanently removed from the
circulatory system. In application, blood circulation is established into the
Hemopurifier(R) via a catheter or other blood access device. Once blood flow has
been established, treatment benefit is immediate as the entire circulatory system
can pass through the Hemopurifier(R) in as little as 15 minutes.
Our wholly owned subsidiary, Exosome Sciences, Inc. (ESI) is focused on the
development of exosome-targeted products and services that improve cancer
diagnosis, provide post-treatment cancer surveillance, and aid in the discovery
of biomarkers that allow doctors to optimize patient therapy. Additional
information regarding Aethlon Medical and Exosome Sciences can be accessed online
at http://www.aethlonmedical.com.
Certain of the statements herein may be forward-looking and involve risks and
uncertainties. Such forward-looking statements involve assumptions, known and
unknown risks, uncertainties and other factors which may cause the actual
results, performance or achievements of Aethlon Medical, Inc. to be materially
different from any future results, performance, or achievements expressed or
implied by the forward-looking statements. Such potential risks and uncertainties
include, without limitation, the capability of the Hemopurifier(R) to reduce
viral loads and other disease conditions or to identify or treat disease
conditions such as cancer, including the ability to capture exosomes and the
impact that potential ability may have on disease conditions, the Company's
ability to raise capital when needed, the Company's ability to complete the
development of its planned products, the ability of the Company to obtain FDA and
other regulatory approvals permitting the sale of its products, the Company's
ability to manufacture its products either internally or through outside
companies and provide its services, the impact of government regulations, patent
protection on the Company's proprietary technology, product liability exposure,
uncertainty of market acceptance, competition, technological change, and other
risk factors. In such instances, actual results could differ materially as a
result of a variety of factors, including the risks associated with the effect of
changing economic conditions and other risk factors detailed in the Company's
Securities and Exchange Commission filings.
Contacts:
James A. Joyce
Chairman, CEO
858.459.7800 x301
jj@aethlonmedical.com
John P. Salvador
Director, Communications & Investor Relations
858.459.7800 x307
jps@aethlonmedical.com
Jon Cunningham
RedChip Companies, Inc.
800.733.2447 x107
jon@redchip.com
SOURCE Aethlon Medical, Inc.
Copyright (C) 2010 PR Newswire. All rights reserved
I would not touch ANX at all right now...
NEPH NEWS..Finally
Ultrafilters to be a Standard Component of MRO Series Water Treatment Systems
RIVER EDGE, N.J., July 6 /PRNewswire-FirstCall/ -- Nephros, Inc. (OTC
Bulletin Board: NEPH), a medical device company developing and marketing
filtration products for therapeutic applications, infection control, and water
purification, today reported that AmeriWater Corporation has adopted the
Nephros Dual Stage Ultrafilter (DSU) as a standard component of its MRO
portable reverse osmosis water treatment systems for dialysis.
"The Association for the Advancement of Medical Instrumentation (AAMI) Renal
Disease and Detoxification Committee has approved the integration of standard
RD52 with the new ISO23500 international standards," said Jim Baker, President
of AmeriWater. "When released, the new standard will significantly lower the
recommended tolerable endotoxin levels for water used to make dialysate. It is
important that portable water systems can meet these standards on a consistent
basis. The Nephros filter provides additional filtration to meet these
standards."
"With the new proposed AAMI standards, it became clear that many of the
dialysis centers would have to work harder to achieve these new standards,
especially the ones that utilize portable RO's because of their sporadic use,"
said Diane Dolan, CEO, AmeriWater. "Our decision to add the Nephros filter as a
standard component on our portables will help ensure that the water used for
dialysis will be of the highest quality for the patients."
"Nephros applauds the proactive step that AmeriWater has taken to meet the
new endotoxin standards and is proud to be working together to provide added
safety to dialysis patients," said Paul A. Mieyal, acting CEO of Nephros.
About Dual Stage Ultrafilters
The Nephros DSU is FDA approved for filtration of biological contaminants
from water and bicarbonate concentrate used in hemodialysis procedures. Within
the U.S., there are approximately 4,500 clinics providing over 50 million
dialysis treatments to 350,000 patients annually. To perform dialysis,
ultrapure water is crucial to the production of dialysate. Dialysis clinics
have water purification systems; however, microbial contaminants can originate
from the water treatment system, the water distribution loop, or the dialysate
concentrates. The Nephros DSU filters particles down to the 0.005-micron level
and addresses dialysate contamination at crucial points: after the reverse
osmosis module and at the dialysis machine entrance from the water distribution
loop. The DSU filter can be used as the last step in the water purification
process to ensure ultrapure water for dialysis procedures. Regular use of
Nephros Dual Stage Ultrafilters offers an affordable safety measure when
utilized with modern water treatment systems and optimally designed
hemodialysis machines.
About MRO Series Water Treatment Systems
The AmeriWater portable MROS and MRO1 water treatment systems are tap water
ready. The compact cabinet RO includes pretreatment options and microbiological
filtration for 1-2 patient use. This unique design has dual chloramines removal
carbon cartridges with a special blended carbon block design that satisfies
AAMI and CMS requirements. Also included inside the cabinet is an optional
anti-scalant system that removes hardness minerals eliminating the need for a
softener. Disinfection is quick and easy. With a simple push of the keypad, the
MRO series can be disinfected with PAA in only one hour. This extremely quiet
complete system is FDA 510K / ISO 13485 and Health Canada registered. The
addition of the Nephros filter completes the MRO by blocking microbiological
contaminants down to 0.005 microns.
About AmeriWater Corporation
AmeriWater is a premier provider of water treatment solutions for dialysis
and health care applications. Established in 1995, AmeriWater is headquartered
in Dayton, Ohio with regional distributors across the Western Hemisphere.
Company founder Jim Baker is a leading industry authority on water quality with
over 35 years experience in the field. For more information, visit
www.ameriwater.com.
About Nephros, Inc.
Nephros, Inc., headquartered in River Edge, New Jersey, is a medical device
company developing and marketing filtration products for therapeutic
applications, infection control, and water purification.
The Nephros hemodiafiltration ("HDF") system is designed to improve the
quality of life for the End-Stage Renal Disease (ESRD) patient while addressing
the critical financial and clinical needs of the care provider. ESRD is a
disease state characterized by the irreversible loss of kidney function. The
Nephros HDF system removes a range of harmful substances more effectively, and
with greater capacity, than existing ESRD treatment methods, particularly with
respect to substances known collectively as "middle molecules." These molecules
have been found to contribute to such conditions as dialysis-related
amyloidosis, carpal tunnel syndrome, degenerative bone disease and, ultimately,
mortality in the ESRD patient. Nephros ESRD products are sold and distributed
throughout Europe.
The Nephros Dual Stage Ultrafilter (DSU) is the basis for the Nephros line of
water filtration products. The patented dual stage cold sterilization
ultrafilter has the capability to filter out bacteria and, due to its
exceptional filtration levels, filter out many viruses, parasites and
biotoxins. Nephros's DSUs are being evaluated at several major U.S. medical
centers for infection control. The DSU has also been selected for further
development by the U.S. Marine Corps for purification of drinking water by
soldiers in the field.
For more information about Nephros, please visit our website at
http://www.nephros.com.
Forward-Looking Statements
Statements in this news release that are not historical facts constitute
"forward-looking statements" within the meaning of the Private Securities
Litigation Reform Act of 1995 (the "PSLRA"). Such statements may be preceded by
words such as "may," "plans," "expects," "believes," "hopes," "potential" or
similar words. For such statements, Nephros claims the protection of the PSLRA.
Forward-looking statements are not guarantees of future performance, are
based on assumptions and are subject to various known and unknown risks and
uncertainties, many of which are beyond Nephros' control. Actual results may
differ materially from the expectations contained in the forward-looking
statements. Factors that may cause such differences include the risks that
Nephros may not be able: (i) to obtain additional funding when needed or on
favorable terms; (ii) to continue as a going concern; (iii) to obtain
appropriate or necessary governmental approvals to achieve its business plan or
effectively market its products; (iv) to have its technologies and products
accepted in current or future target markets; (v) to demonstrate in
pre-clinical or clinical trials the anticipated efficacy, safety or cost
savings of products that appeared promising to Nephros in research or clinical
trials; or (vi) to secure or enforce adequate legal protection, including
patent protection, for its products. More detailed information about Nephros
and the risk factors that may affect the realization of forward-looking
statements is set forth in Nephros' filings with the SEC. Investors and
security holders are encouraged to read these documents on the SEC's website at
http://www.sec.gov/. Nephros does not undertake to publicly update or revise
its forward-looking statements as a result of new information, future events or
otherwise except as required by law.
SOURCE Nephros, Inc.
/CONTACT: Eileen M. Sukumaran, Nephros, Inc., +1-201-343-5202
/Web site: http://www.nephros.com
Click here to go to Dow Jones NewsPlus, a web front page of today's most
important business and market news, analysis and commentary:
http://www.djnewsplus.com/nae/al?rnd=GFXa1z9WX%2Fr6rfHaX%2BJ3Ng%3D%3D. You can
use this link on the day this article is published and the following day.
(END) Dow Jones Newswires
07-06-10 1600ET
16:00 070610
Thanks...Interesting
Insider Buying Alert....SPPI
ISSUER: SPECTRUM PHARMACEUTICALS INC
SYMBOL: SPPI
SOURCE: Form 4
FILER: MEHTA DILIP J
TITLE: Director
DATE TRANSACTION SHARES PRICE VALUE
7/6/10 Purchase 10,000 $3.74 $37,367
OWNERSHIP: 32,000 (Direct)
The Form 4 is filed with the Securities and Exchange Commission by insiders
to report transactions in their companies' shares. Open market purchases
and sales must be reported within two business days of the transaction.
Insider Data Source: The Washington Service
(info@washingtonservice.com or 301-913-5100)
Click here to go to Dow Jones NewsPlus, a web front page of today's most
important business and market news, analysis and commentary:
http://www.djnewsplus.com/nae/al?rnd=GFXa1z9WX%2Fr6rfHaX%2BJ3Ng%3D%3D. You can
use this link on the day this article is published and the following day.
(END) Dow Jones Newswires
07-06-10 1511ET
15:11 070610
Why do you think Organic Science may be HESG?
a extremely low volume sell order trade hit the bid ,but it is back to .45....no issues
krzyvstr,
The Fancy Food show just ended and the Whole Food order was just placed on the shelves. I am sure we will hear something on both soon.You can call Natures Peak at anytime and talk to Paul. His number is on the ibox.
BioElectronics Corp. is Today's Focus Stock on MicroStockProfit.com
globenewswire
Press Release Source: MicroStockProfit.com On Thursday July 1, 2010, 6:50 am EDT
DALLAS, July 1, 2010 (GLOBE NEWSWIRE) -- MicroStockProfit.com announces an investment report featuring BioElectronics Corp. (Pink Sheets:BIEL - News). The report includes financial, comparative and investment analyses, and recent company news that you need to know to make an educated investment decision.
Our trade alerts and ideas are provided free to investors. Simply use your email address to subscribe with http://www.microstockprofit.com to get the inside track on our next red-hot alert.
The full report is available at: http://www.microstockprofit.com/lp/BIEL
BIEL's recent volatility has been greater than normal. This is evidenced by the increased distance between the upper and lower Bollinger Bands. These bands measure volatility using standard deviation and a large width is due to high volatility. Additionally, BIEL is trading within its Bollinger Bands. This is a normal condition and suggests that the stock is neither overbought nor oversold relative to the recent price action.
BioElectronics Corp. (BIEL) designs, develops and markets a variety of drug-free, anti-inflammatory patches for a range of medical indications. The Company's patch products, which are marketed under the name ActiPatch Therapy, deliver pulsed electromagnetic field therapy, an anti-inflammatory and pain relief therapy. The ActiPatch Therapy products combine a miniaturized microchip, power source and antenna in a soft, flexible outer envelope. When applied to the body, these devices deliver a pulsed radio frequency signal into the body on a 27 megahertz (MHz) frequency wave that induces a low frequency electromagnetic field to damaged cell tissue.
Message Board Search for BIEL: http://www.boardcentral.com/boards/BIEL
In the report, the analyst notes:
"BIEL, on April 1, 2010, announced the completion of its full year audit and the filing of Form 10K with the Securities and Exchange Commission. BIEL is now a fully reporting company however has not reported since the financial statement for the period ending September 30, 2009.
"BIEL announced today that its Allay(TM) Menstrual Pain Therapy product has been approved for over the counter sale by Health Canada for the treatment of menstrual pain symptoms, including cramps and abdominal pain, and for reducing the use of pain medication associated with menstruation, while ActiPatch(TM) is now approved by the South Korea Food and Drug Administration (KFDA) for reduction of muscle pain."
To read the entire report visit: http://www.microstockprofit.com/lp/BIEL
See what investors are saying about BIEL at penny stock forum
MicroStockProfit.com Disclosure
MicroStockProfit.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. MicroStockProfit.com is a Web site wholly owned by BlueWave Advisors, LLC. Neither MicroStockProfit.com nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. Please read our report and visit our Web site, MicroStockProfit.com, for complete risks and disclosures.
Contact:
MicroStockProfit.com
Brian Johnson
1-888-307-2850
info@microstockprofit.com
Consumer Reports investigation should fuel Inergetics, Inc. (OTC: NRTI)
Written by M.E.Garza
Monday, 28 June 2010 07:56
3diggsdigg
A damning Consumer Reports investigation threatens to cripple two of the leading brands in the $2.7 billion sports nutrition marketplace according to a report from CNBC's Darren Rovell. That news could bode very well for penny stock, Inergetics, Inc. (NRTI.OB), whose medically designed and scientifically tested nutritional drinks include products in that same sports nutrition vertical.
The report, released earlier this month online and in its July issue, reveals that lab tests of both EAS Myoplex and Muscle Milk products had more than trace levels of arsenic, lead and cadmium. This is a direct hit against the market leaders in protein drinks which alleges that these brands that had the highest concentration of toxic elements. This could be a big opportunity for NRTI to step in and push their Surgex sports drink line as a strong competitor to Muscle Milk; which is a strategy the company has been quietly working on and preparing for over two years.
Already, many NBA teams have been using NRTI's breakthrough Surgex drink, which was specifically developed and scientifically tested to help athletes rebuild muscle and "bounce back" much faster than those other nutritional drink supplements available on the market.
At the end of March, Mark C. Mirken, President and Chief Operating Officer of NRTI told us: "Our sports product, Surgex, is an independently, medically
validated product with a banned substance control group of athletes that is manufactured by us. It is used in the NBA and the NFL and it's success comes from the work that went into developing it with strength and conditioning coaches and that product is about to have a significant commercial debut- predicated on a relationship that we are creating with one of the largest powdered drink manufacturers in the world in maximum human performance."
Rutgers University supported NRTI's claims by publishing two articles about the sports drink product which substantiated the product's efficacy in athletes. Other reports and scientific publications are said to be following shortly.
Perhaps even more intriguing is the fact that the U.S. Government has taken an interest in several of the company's drink verticals and that NRTI may see substantial purchase orders for both Surgex and some of the company's other nutritional vertical products in the very near term. "Orders from government agencies and military academies will be much bigger than anyone has anticipated," said one source familiar with the situation. "One federal emergency response agency seems particularly interested in stocking up with the nutritional product and it makes sense that they would be."
Is the biggest challenge for NRTI still credibility? Consider for a moment that they are a company still in its infancy and listed on the OTCBB exchange. While the company continues to show us that it is working aggressively behind the scenes to move the stock to a bigger exchange “in a shorter than expected time frame," half the battle for today's investors is trying to figure out which of these bulletin board companies are real and which are virtual ATM machines for the people who run them. That's a reality in these smaller exchanges, but also a sad growing reality on some of the larger exchanges as well.
Still, when we start seeing real movement and players with known reputations getting involved in "baby biotechs," like NRTI, we can't help but take notice.
Given the news and recent developments, the company has been attracting attention from major players in the sports and nutritional drinks industry. They are said to also be attracting the attention of hall of fame sports figures- one of them is rumored to be not only signing on as a spokesman, but also as a major investor. While the company is not commenting on the rumor, our sources tell us that we may hear news about this well known star and that his new relationship with NRTI as soon as this week.
The company’s sports drink vertical appears just about ready for blast off.
"The marketplace is definitely waiting for this," said Mirken. "We know that because of the calls we constantly get from a number of the teams, from strength and conditioning coaches and that there is no product on the market that has the proven ability to be able to generate the 'recovery reaction' that we are able to in the blood through the use of our proprietary superoxide dismutase- the body's primary antioxidant defense enzyme. If an athlete can work out and recover quickly and then work-out and recover quickly, his ability to optimize his performance is really the key to making this product a global success."
As an investor, one also has to appreciate the fact that the management team of the upstart bio-nutraceutical company is focused on the swift, but efficient execution of their business plan. Since we first covered them a couple of months ago, the company has been working on it's re-branding (they changed from Millennium Biotechnologies to Inergetics, Inc. [OTC: NRTI] and the banking/finance team has "been busy getting it's financial house in order" as it prepares to move quickly into the commercialization phase.
Inergetics, Inc.
0.01 -0.00 (-8.89%)
Intraday | 3 Month | 6 Month | 1 Year
Quotes delayed at least 20 mins.
What we like most, however, is that shares of this bio-nutraceutical company can still be had for next to nothing. We've seen this before. When BioMedReport's Vinny Cassano started tracking another biotech drink company- Celsius Holdings (Nasdaq: CELH)- in 2008 when it was still listed on the bulletin board exchange and trading at just under $.03 cents. By mid-April of this year, shares were trading above $4 per share. Now, just as we saw with Celsius back then, we recognize that the upside for NRTI is much higher than the downside. Especially at these prices. In fact, we feel a "strong buy" rating is in order given the shaky state of the market and the very friendly share prices.
Our sentiment grows even stronger given the fact that the management team has now successfully rebranded the company. The team changed the name and reduced their debt- first by $2.6 million and then by an additional $700,000. Now with well over $3 million in liabilities off the balance sheet the company finds itself with 61% less debt (which was $18 million approximately one year ago).
NRTI has re-surfaced both its Surgex and Resurgex product websites. There you will find a re-launch of the company's "long term care" and "sports" verticals with new product designs.
We are told that the company is in process of building out inventory of their powder formulation on the sports side (Surgex).
For those of you who have asked about the ability to sample the drink, consumers should be able to order directly from the website within the next 30 days. Already, many NBA teams have been using the breakthrough drink, known for helping athletes rebuild muscle and "bounce back" much faster than other nutritional drink supplements available on the market.
Sources, including Merken, have BioMedReports that the company is extremely focused on producing revenue and profits. We see evidence of that when we hear of scheduled meetings which are to take place early this week with two mega-nutrition sector outlets, GNC and Vitamin Shoppe. The sole purpose of those meetings is to procure purchase orders.
The fact that the company has been actively courting a new Chief Financial Officer additionally points to the start of the commercialization phase for the company. This is not a stock awaiting multi phase trial results or FDA approval process. The company has paid its dues in the laboratory formulating and testing their products, now we sense that some very positive business dealings will start to move things along quickly for Inergetics.
We also anticipate a few pleasant surprises as the company starts to push product through some direct marketing channels. One group is reportedly close to entering into a relationship to purchase, re-sell and pay for all the marketing expenses relating to their direct to consumer campaigns. A publicly announced large purchase order for product would signal a successfully consummated business deal with that company.
Add this still intriguing development to what Merken told us:
"One of our board members, Ken Sadowsky [whom we are told also invested substantial money into the company], sat on the board of Vitamin Water when it was sold to Coke and he has been shifting us through the process and we're now (still) in discussions with two of the largest bottling companies in the world who are looking for a product such as this in the functional beverage category, so as you step back and look at us, we are a company that has at least three engines: One in oncology and immunocompromised... One in long term care and assisted living. [the company recently announced a relationship with a billion dollar pharmaceutical company which is expanding their reach into the long-term care space]... Finally, one in the Sports product which is about to be commercialized... We expect some significant success..."
We're will continue alerting readers to both pending and current developments and fully expect that when NRTI announces the company's new spokesperson, investors will see the news as one more key piece of credibility falling into place. If executed properly, share prices should continue to rise given the anticipated excitement and news items- both of which should start to stream in during the coming weeks and months ahead.
They needed funding to get the product out...They now have the funding,so they are able to distribute.Plus they had to take care of Whole Foods first.
ANVR..The Sky's the Limit for Avanir Pharmaceuticals
by: Jeremy Richards June 27, 2010
Recent accomplishments for Avanir (AVNR) marked the most exciting quarter in the history of the company, and it is highly likely that big news is on the near-term horizon. Avanir’s share price closed at $2.67, a gross undervaluation, in Friday's trading session. I expect Avanir’s share price to easily double prior to October when the FDA is expected to approve its key drug, Zenvia. And the stock price should easily reach $10 per share by early 2011, the expected launch time of Zenvia. The details of my analysis will be presented later in this article, but first, I will address the key drivers that make Avanir a compelling “buy and buy more” proposition:
Promising Pipeline with Expandable Applications
The Company’s lead product candidate, Zenvia (dextromethorphan hydrobromide/quinidine sulfate), has completed three Phase III clinical trials for the treatment of pseudobulbar affect (PBA) and has completed a Phase III trial for the treatment of patients with diabetic peripheral neuropathic pain (DPN pain). In the past 3 months, three firms (Wedbush, Cantor Fitzgerald, and Cannacord Adams) gave price targets that are more than 2 to 3 times the current share price.
Wedbush analyst Mike King describes, "Avanir is currently an off-the-radar-screen company developing Zenvia, a late-stage asset for the treatment of pseudobulbar affect. PBA is itself a little-recognized, but serious and debilitating, disorder that typically is a consequence of any one of several neurologic insults, such as MS, ALS, or TBI...An investment in Avanir is reminiscent of the opportunity presented to investors when Fampridine-SR was in early development for Acorda (ACOR), which currently boasts a valuation of ~$1.5 billion."
Quite noteworthy is that the company should have a broad label for all patients that have PBA. As per Keith Katkin, CEO of Avanir, " as has been the agreement all along with the FDA, if we study Zenvia in two separate neurologic populations, like we did in the STAR trial, then that should be sufficient for a broad label for all patients that have PBA." What is most exciting is the company’s strategy for future expansion, using Zenvia PBA approval as the express gateway to approval of many different types of pain applications, making the sky the limit for Avanir.
2Q2010 Developments
Avanir’s management accomplished several key milestones in the second quarter:
1. Patent protection - The Company received long-term (15 year) patent protection on Zenvia, securing its monopoly on Zenvia for years to come.
2. Extremely Positive Data - Avanir provided extremely positive safety and efficacy data at the American Academy of Neurology meeting and American Psychiatric Association meeting. They also showed tolerability with common drugs Paroxetine (a common antidepressant) and Memantine, a drug Merz +Co and Forest Labs (FRX) market for ALS patients. Commenting on the AAN meeting, Keith Katkin, CEO of Avanir, states "...the physician interest level in PBA is significant and reinforces our belief there is a large unmet medical need". As a Merriman Analyst commented, "Avanir Pharmaceuticals is advancing its lead product, Zenvia, for the unique indication of pseudobulbar affect, a hitherto little-known neurological condition that may affect millions of individuals…In our view, the Phase III STAR trial data are compelling…” Evidence of the excitement about Zenvia is apparent when looking at the stock price action after the Jeffries & Company (JEF) Health Sciences presentation by Avanir on June 8. The stock price had greater than a 25% upward move in a matter of a few days. Also notable is the trading volume in the $5.00 December calls. And furthermore, Avanir boasts institutional holders such as Blackrock, which is one of the most respected hedge funds on the street.
3. Early start on marketing/awareness efforts- Awareness of PBA is growing and the management team is diligently preparing for commercial launch. Top talent Michael McFadden was hired. Mr. McFadden previously managed markets at Amylin Pharmaceuticals (AMLN). When asked by an analyst of upcoming events prior to approval, Keith Katkin responded, "...you'll see PBA awareness advertorials within all of the medical journals. You'll also see them in the patient-focused journals…"Also, Avanir will attend "a dozen" different neurology and psychiatry meetings. Also, quite noteworthy is that AVNR partnered with ITV and PBS and will be airing a series on PBS stations (estimated late-June to early July) about the impact of PBA on patients' lives. Cannacord Adams analyst comments “AAN doctor opinion on Zenvia has been positive; we think that Zenvia will see good patient and doctor acceptance…”
4. Raised Capital – Debt-freeAvanir raised over $26 million through a recent stock offering such that Christine Ocampo, CFO of Avanir, stated "we expect our current cash on hand will be adequate to fund continuing operations and the clinical development of Zenvia through the anticipated FDA approval decision date..."
5. FDA Submission - The Company provided the FDA with all data needed to assess Zenvia in PBA. Approval is extremely likely as Zeniva's two major components are not new molecular entities and the response letter submitted was solid. After reviewing the submission, Cannacord analyst commented “…any delay would be minor and not reflect negatively on Zenvia’s approvability or sales potential.” Investors will remember Dendreon’s (DNDN) situation after receiving an approvable letter from the FDA, its engagement in subsequent studies, and ultimately approval which turned a $4 stock into one that now trades above $37.
Valuation
In my valuation of the company, I will disregard the current royalties received from GlaxoSmithKline (GSK) on Abreva sales (approximately $3-$4 million expected this year) and will focus solely on Zenvia, which would be the first drug approved to treat PBA. Per Randall Kaye, Chief Medical Officer, the prescribed period of time on the drug would be "indefinite," not a 12-week limit. This translates into increased revenue potential. And the company has supporting data to prove efficacy and safety over time, as they have over 100 patients with over 2 years exposure to Zenvia.
As mentioned above, Mike King of Wedbush compares the company to one that has a market cap of $1.5 billion. That number is above, but not far off from, my estimates. Cantor analyst says, "We think AVNR is significantly undervalued given its current market capitalization and near-term FDA approval potential for its lead product, Zenvia, to treat pseudobulbar affect plus potential value maximizing follow-on indications." Merriman analyst states, “The company’s market cap is significantly undervalued due to a previous regulatory delay and lack of knowledge of the PBA indication. In our view, the Phase III STAR trial data are compelling…”
Let’s examine a price/sales multiple. Cantor Fitzgerald estimates $675 million in peak sales for Zenvia, ramping up and seeing those peak sales in 2015. Personally, I think the estimate is a bit conservative when one factors the indefinite prescribed period and the other applications of Zenvia that should be approved following the PBA approval. But, let’s go with Cantor’s sales estimate. Although there is wide variation in price/sales ratios, the average biotech trades at 3 times peak sales. Since Avanir has rights to the drug longer than most drug companies (15 years), it could reach much higher multiples. But, even using a more conservative estimate of half that figure (1.5 times price/sales), the market cap of Avanir should be over $1 billion. That’s approximately $10 per share, indeed compelling with a potential upside of over 400%! And for more short-minded investors, there are two near-term catalysts:
1. A Barron’s article this weekend mentions that 9 pharma companies (Pfizer: PFE, Merck: MRK, Eli Lilly: LLY, Bristol Myers: BMY, Novartis: NVS, Roche: RHHBY.PK, AstraZeneca: AZN, Sanofi-Aventis: SNY, and Glaxo Smith Kline: GSK) are undervalued and could rally 30%, and
2. There should be a nice run prior to FDA acceptance, easily pushing the stock to $6. I’ve taken a sizable position and am quite ready to enjoy the ride!
NEOP is a great play,a lot of insider buying
No question
This stock is totally under radar,but not for long...When I talked to CEO he said they are working on increasing volume.I have checked Walgreen's stores and they have nothing like Thermafreeze and with Duanne Reed stores taking them on and doing well and now Walgreen's buying out Duanne Reed we could be looking at a huge opportunity.
Stock_Picker ,thank you for your previous comments.You could be right, but I do not see this theory at all. Remember as I said before,anything can happen ,but Paul and Robert have millions of there own money in this.and from the recent PRs they are working to grow the structure,this to me is strong evidence that thing are moving in the right direction.After talking to all involved ,this is the real deal,now will it succeed? My option is yes.
KngmAz, Please don't insult me when I spent my time to go to the show and share my DD with the board.Paul and Roberts shares are restricted,they have all the motivation to increase share holder value,because their restricted shares will be worth more. I did have the conversation with Paul.
He is extremely nice and is dedicated to Natures Peak. I have never seen a guy work so hard.
I did and I asked Paul about it ...it should ship in the next few days.
Natures Peak Pictures Promised from the Kehe Show 2010 in Chicago!
You will see me and Paul,Paul,Natures Peak Booth,Paul working with a large distributor and writing an order.
http://investorshub.advfn.com/uimage/uploads/2010/6/24/ussqfPicture_014.jpg
http://investorshub.advfn.com/uimage/uploads/2010/6/24/qmeztPicture_010.jpg
http://investorshub.advfn.com/uimage/uploads/2010/6/24/wmaxnPicture_006.jpg
http://investorshub.advfn.com/uimage/uploads/2010/6/24/[bqxoPicture_009.jpg
http://investorshub.advfn.com/uimage/uploads/2010/6/24/zmoopPicture_002.jpg
Snwbrd check out post #1143 Have a great day..
Alert...Just talked to Thermafreeze Exec. He stated that they are for sure going with an Athlete spokesperson to promote Thermafreeze. It is just a timing issue.There will also be another QVC show scheduled soon.Financials will be out in less than a month,the audits are being done now.No sales figures will be released before the financials are released.They will be moving off the Pinks for sure soon,but not sure if they are going OTCBB or maybe a bigger board.They are currently in talks with Walgreen's on carrying their products nationwide.Good stuff guys....
Not sure ,I will try to find out
ThermaFreeze, Inc. (TZPC) – Continues its Aggressive Retail Distribution Roll-Out
by Joe on June 23, 2010
ThermaFreeze (TZPC) issued a press release this morning that their retail distribution has now a reach from coast to coast. They also announced that they have even received orders from the U.S. territory of Puerto Rico. The Company is well positioned for a strong revenue ramp for the second half of 2010 and 2011. They have already received orders from large retailers for next year distribution.
ThermaFreeze’s products are now sold in over 1,500 stores nationwide. In addition, the products were recently promoted on QVC network, were the products sold out in a few minutes, exceeding everyone’s expectations. QVC has already invited the Company back for multiple appearances throughout the summer. See the following link for the infomercial from QVS, which will provide a good understanding of the product:
http://www.qvc.com/qic/qvcapp.aspx/view.2/app.detail/params.item.K30123.desc.ThermaFreeze-Set-of-15-Reusable-Ice-Sheets
We are very bullish on this stock and believe the revolutionary patented ThermaFreeze ice-replacement product can become a household name. Please send an email to jnoel701@yahoo.com if you would like a free sample of this product. I believe you will understand why we are excited about the strong potential for the product.
Insider Buying Alert...SPPI
SOURCE: Form 4
ISSUER: SPECTRUM PHARMACEUTICALS INC
SYMBOL: SPPI
FILER: SHROTRIYA RAJESH C
TITLE: Chairman of the Board
DATE TRANSACTION SHARES PRICE VALUE
6/24/10 Purchase 10,000 $3.84 $38,367
OWNERSHIP: 1,173,486 (Direct)
The Form 4 is filed with the Securities and Exchange Commission by insiders
to report transactions in their companies' shares. Open market purchases
and sales must be reported within two business days of the transaction.
Insider Data Source: The Washington Service
(info@washingtonservice.com or 301-913-5100)
Click here to go to Dow Jones NewsPlus, a web front page of today's most
important business and market news, analysis and commentary:
http://www.djnewsplus.com/nae/al?rnd=s3H2gYR4UuCneMVXHkHFzw%3D%3D. You can use
this link on the day this article is published and the following day.
(END) Dow Jones Newswires
06-24-10 1401ET
14:01 062410
NEOP News...Neoprobe Recommended for $1 Million Lymphoseek Grant from Ohio Third Frontier
Funds to accelerate head and neck cancer clinical program, exploration in other
cancer types
DUBLIN, Ohio, Jun 24, 2010 (BUSINESS WIRE) -- Neoprobe Corporation (NEOP), a
diversified developer of innovative biomedical surgical oncology products, today
announced that Ohio's Third Frontier Commission has voted to award a grant of $1
million to fund ongoing development of Neoprobe's Lymphoseek(R)
radiopharmaceutical initiative, subject to the review of the State Controlling
Board. The Ohio Third Frontier grant will be used to accelerate clinical testing
for Neoprobe's Phase 3 trial in patients diagnosed with head and neck squamous
cell carcinoma. This trial is intended to expand the proposed product labeling
for Lymphoseek following an initial broader product label. Neoprobe was among
eight companies awarded Medical Imaging Program grants by the Commission.
Frederick O. Cope, Ph.D., Neoprobe's Vice President of Pharmaceutical Research
and Clinical Development, said, "In selecting Neoprobe, the Ohio Third Frontier
will help us accelerate the application of Lymphoseek into head and neck cancer
treatment and other cancer types and help patients who otherwise might not
receive this innovative treatment. We are excited to have been recommended to
receive funds from the Ohio Third Frontier for our clinical program,
demonstrating Ohio's strong commitment to furthering economic development in the
biotechnology industry in this region."
Neoprobe's Lymphoseek initiative involves a collaboration of several Ohio-based
companies as well as leading cancer centers across the United States and in
Europe. Neoprobe's collaborators on this grant included Cardinal Health, Inc.
(Dublin, OH), Phylogeny, Inc. (Columbus, OH), StatKing Consulting (Fairfield, OH)
and Integrated Bioscience Solutions, LLC (Loveland, OH).
Lymphoseek is a proprietary radioactive tracing agent being developed for use in
connection with gamma detection devices in a surgical procedure known as
Intraoperative Lymphatic Mapping. A Phase 3 multi-center clinical trial for
Lymphoseek in patients with breast cancer or melanoma has been successfully
completed and a second Phase 3 clinical study to evaluate the efficacy of
Lymphoseek as a sentinel lymph node tracing agent in patients with head and neck
squamous cell carcinoma is underway.
Penny Stalker, those reports were from my DD,we should hear from EVRN soon.
SPPI News..SPPI Appoints James Shields as Chief Commercial Officer
-- Company Continues Its Focus on Maximizing the Value of Its Two Marketed
Anticancer Drugs - ZEVALIN(R) and FUSILEV(R) - and Advancing Its Late
Stage Oncology Portfolio
IRVINE, Calif.--(BUSINESS WIRE)--June 23, 2010--
Spectrum Pharmaceuticals, Inc. (NasdaqGM: SPPI), a commercial-stage
biotechnology company with a focus in oncology and hematology, today announced
that it has appointed James E. Shields, a seasoned pharmaceutical sales
executive with a proven track record of establishing and leading commercial
operations, to the position of Senior Vice President and Chief Commercial
Officer. Mr. Shields' appointment is an important component of the Company's
continued focus on maximizing the growth potential of its ZEVALIN(R) and
FUSILEV(R) brands, and as it makes launch preparations for its other late-stage
drugs in the near future.
"We have strengthened Spectrum Pharmaceuticals' management team with the
addition of Jim, an industry veteran who brings a wealth of knowledge and
applied commercial experience," said Rajesh C. Shrotriya, M.D., Chairman, Chief
Executive Officer, and President of Spectrum Pharmaceuticals. "Over the past
month, Jim has immersed himself in the Company's sales and marketing
organization. With an objective of optimizing and streamlining the sales force
structure that focuses on results, he has appointed two field-based Vice
Presidents -- a Vice President of National Sales and Field Operations, and a
Vice President of Government Affairs and Business Solutions. His
results-oriented, hands-on approach, in the near-term, is expected to be an
important driver for revenue, thereby helping to increase shareholder value."
"I am pleased, honored, and very excited to be a part of Spectrum
Pharmaceuticals and to work in conjunction with Dr. Shrotriya and the entire
Spectrum team," said Mr. Shields. "Together, we will work to achieve Spectrum's
corporate goals and fulfill the vision of improving the lives of cancer
patients -- which has been the Company's foundation and driving force from the
beginning."
Mr. Shields' experience spans Fortune 500, biotechnology, as well as
small-to-mid-size companies with an emphasis on establishing and leading
successful commercial sales operations. Mr. Shields' oncology sales experience
includes serving as the Vice President of Sales for Oncology and Injectable
Products for MGI Pharmaceuticals, and Vice President of Sales and Marketing of
Oncology for Supergen. Mr. Shields also held positions of increasing
responsibility with several pharmaceutical companies, including Centocor,
Bristol-Myers Squibb, ICI, and Stuart Pharmaceuticals. Mr. Shields was most
recently with Teva Pharmaceutical Industries Limited. Mr. Shields earned his
Bachelor's Degree from the University of Kentucky.
About Spectrum Pharmaceuticals
Spectrum Pharmaceuticals is a commercial-stage biotechnology company with a
focus in oncology and hematology. The Company's strategy is comprised of
acquiring, developing and commercializing a broad and diverse pipeline of
late-stage clinical and commercial products. In addition to continuing to build
an efficient in-house clinical research organization with regulatory and data
management capabilities, the Company has established a commercial
infrastructure to market its drug portfolio. The Company markets two oncology
drugs, ZEVALIN(R) and FUSILEV(R), and has two drugs in late stage development,
apaziquone and belinostat, along with a diverse pipeline. The Company also
leverages the expertise of its worldwide partners to assist in the execution of
its strategy. For more information, please visit the Company's website at
www.sppirx.com.
Forward-looking statement -- This press release may contain forward-looking
statements regarding future events and the future performance of Spectrum
Pharmaceuticals that involve risks and uncertainties that could cause actual
results to differ materially. These statements include but are not limited to
statements that relate to our business and its future, Spectrum's ability to
identify, acquire, develop and commercialize a broad and diverse pipeline of
late-stage clinical and commercial products, leveraging the expertise of
partners around the world to assist us in the execution of our strategy, and
any statements that relate to the intent, belief, plans or expectations of
Spectrum or its management, or that are not a statement of historical fact.
Risks that could cause actual results to differ include the possibility that
our existing and new drug candidates may not prove safe or effective, the
possibility that our existing and new drug candidates may not receive approval
from the FDA, and other regulatory agencies in a timely manner or at all, the
possibility that our existing and new drug candidates, if approved, may not be
more effective, safer or more cost efficient than competing drugs, the
possibility that our efforts to acquire or in-license and develop additional
drug candidates may fail, our lack of revenues, our limited marketing
experience, our dependence on third parties for clinical trials, manufacturing,
distribution and quality control and other risks that are described in further
detail in the Company's reports filed with the Securities and Exchange
Commission. We do not plan to update any such forward-looking statements and
expressly disclaim any duty to update the information contained in this press
release except as required by law.
SPECTRUM PHARMACEUTICALS, INC. (R), ZEVALIN(R), and FUSILEV(R) are registered
trademarks of Spectrum Pharmaceuticals, Inc. REDEFINING CANCER CARE(TM) and the
Spectrum Pharmaceutical logos are trademarks owned by Spectrum Pharmaceuticals,
Inc.
(c) 2010 Spectrum Pharmaceuticals, Inc. All Rights Reserved.
CONTACT: Spectrum Pharmaceuticals, Inc.
Paul Arndt
Senior Manager, Investor
TDLP News..Transdel Pharmaceuticals to Present at OneMedForum New York 2010
LA JOLLA, Calif., June 23, 2010 /PRNewswire via COMTEX/ -- Transdel
Pharmaceuticals, Inc. (TDLP) today announced that Transdel management will
present a company overview at the OneMedForum New York 2010 Emerging Company
Finance Conference in New York, NY on Wednesday, June 30, 2010 at 12:00 p.m.
Eastern Time.
Interested parties can access a live webcast via the Internet by visiting the
Investor Relations section of the Company's Web site at
http://www.transdelpharma.com.
About Transdel Pharmaceuticals, Inc.
Transdel Pharmaceuticals, Inc. (TDLP) is a specialty pharmaceutical company
developing non-invasive, topically delivered products. The Company's
innovative-patented Transdel(TM) cream formulation technology is designed to
facilitate the effective penetration of a variety of products through the tough
skin barrier. Ketotransdel(R), the Company's lead pain product, has successfully
completed a Phase 3 clinical trial and utilizes the Transdel technology to
deliver the active drug, ketoprofen, a non-steroidal anti-inflammatory drug
through the skin directly into the underlying tissues where the drug exerts its
well-known anti-inflammatory and analgesic effects. The Company intends to
leverage its Transdel(TM) platform technology to expand and create a portfolio of
topical products for a variety of indications. The Company is actively pursuing
partnerships with companies to expand its product portfolio for pharmaceutical
and cosmetic/cosmeceutical products. For more information, please visit
http://www.transdelpharma.com.
Safe Harbor Statement
The Company cautions you that the statements included in this press release that
are not a description of historical facts are forward-looking statements. These
include statements regarding: the Company's interpretation of the results of its
Phase 3 clinical trial for Ketotransdel(R); the Company's ability to obtain
regulatory approval to market Ketotransdel; and the Company's ability to complete
additional development activities for products utilizing its proprietary
transdermal delivery platform. Actual results may differ materially from those
set forth in this press release due to the risks and uncertainties inherent in
the Company's business, including, without limitation: the outcome of the final
analyses of the data from the Phase 3 clinical trial may vary from the Company's
initial conclusions; the FDA may not agree with the Company's interpretation of
such results or may challenge the adequacy of the Company's clinical trial design
or the execution of the clinical trial; the FDA may continue to require the
Company to complete additional clinical trials for Ketotransdel(R) before the
Company can submit a 505(b)(2) NDA application; the results of any future
clinical trials may not be favorable and the Company may never receive regulatory
approval for Ketotransdel(R); and the Company's current need to raise additional
funding to complete its product development plans. More detailed information
about the Company and the risk factors that may affect the realization of
forward-looking statements is set forth in the Company's filings with the
Securities and Exchange Commission, including its Annual Report on Form 10-K and
its Quarterly Reports on Form 10-Q filed with the SEC. Such documents may be read
free of charge on the SEC's web site at http://www.sec.gov. You are cautioned not
to place undue reliance on these forward-looking statements, which speak only as
of the date hereof. All forward-looking statements are qualified in their
entirety by this cautionary statement and the Company undertakes no obligation to
revise or update this press release to reflect events or circumstances after the
date hereof. This caution is made under the safe harbor provisions of Section 21E
of the Private Securities Litigation Reform Act of 1995.
SOURCE Transdel Pharmaceuticals, Inc.
Copyright (C) 2010 PR Newswire. All rights reserved
BIEL News..BioElectronics Welcomes New Additions to Marketing Team
FREDERICK, MD, Jun 23, 2010 (MARKETWIRE via COMTEX) -- BioElectronics Corporation
(PINKSHEETS: BIEL), developers of innovative pain-relieving medical devices,
today announced new additions to their marketing team, comprised of Hudson Levy
(Brand Manager for ActiPatch(TM)) and Georgianna Golematis (Brand Manager for
Allay(TM)).
"Our new team members will leverage a wealth of expertise in communications and
healthcare marketing to manage the brands that BioElectronics represents," said
Dr. Richard Staelin, Chairman of the Board of BioElectronics Corporation. "We're
excited to have such an accomplished team representing our brands."
Arnon Horev, Vice President of Sales and Marketing Horev has an extensive
healthcare sales and marketing background, mainly from his work at Johnson &
Johnson and Bristol-Myers Squibb. He holds an MBA degree from the Fuqua School of
Business at Duke University, with a concentration in Marketing and Decision
Sciences, and a Health Sector Management certificate. He received his B.Sc. in
Life Sciences from Ben Gurion University of the Negev in Israel. Horev is a
recipient of Fuqua merit based scholarship and the winner of the IBM Marketing
Case Competition.
Hudson Levy, Brand Manager for ActiPatch Levy is responsible for all marketing
and implementation of strategic planning for the ActiPatch brand.
Levy holds an MBA from Duke University's Fuqua School of Business, as well as a
Master's degree in Engineering Management and a Bachelor's degree in Mechanical
Engineering. Prior to joining BioElectronics, Hudson spent three and a half years
at Johnson & Johnson where he completed their Leadership Development Program.
While at the company, Hudson led projects ranging from new product development to
sales strategy, as well as brand management. Most recently, Hudson developed a
launch strategy for one of J&J's newest medical devices which was introduced
earlier this year.
Georgianna Golematis, Brand Manager for Allay Golematis is responsible for all
marketing and implementation of strategic planning for the Allay brand.
Prior to joining BioElectronics, Georgianna worked for IDEA Fund Partners, a VC
firm in Research Triangle Park, NC. There, she was responsible for due diligence,
financial modeling, and marketing strategy consultation for Hi-Tech and
Healthcare investments. Before IFP, Georgianna was a Senior Engineer at General
Dynamics. There, she led the product development of software applications for
future technologies.
Georgianna holds an M.B.A. and a Certificate in Health Sector Management from
Duke University's Fuqua School of Business and a B.S.E. in Computer Science
Engineering from the University of Michigan.
About BioElectronics Corporation BioElectronics Corporation (PINKSHEETS: BIEL) is
the maker of safe, inexpensive, drug-free medical devices and patches that
deliver pulsed electromagnetic energy to relieve pain and inflammation. The
Company's wafer thin patches contain an embedded microchip and battery that
deliver pulsed electromagnetic energy, a clinically proven and widely accepted
anti-inflammatory and pain relief therapy that heretofore has only been possible
to obtain from large, facility-based equipment. BioElectronics markets and sells
its current products under the brand names ActiPatch(TM), RecoveryRx(TM),
Allay(TM) Menstrual Pain Therapy and HealFast(TM) Therapy for cats, dogs and
horses. The Company is headquartered in Frederick, MD. For more information,
visit http://www.bielcorp.com.
MEDIA CONTACT:
Hanni Itah
SS|PR
(847) 415-9324
Email Contact
SOURCE: BioElectronics Corporation
http://www2.marketwire.com/mw/emailprcntct?id=3E31FD63DBA6771C
Copyright 2010 Marketwire, Inc., All rights reserved.
Thats true Pennygold...FDA approvals have been delayed in the past,however anything can happen.
Remember....POZEN to Present at the Wells Fargo Securities 3rd Annual Healthcare Conference Tomorrow.
businesswire
Press Release Source: POZEN Inc. On Wednesday June 16, 2010, 7:30 am EDT
CHAPEL HILL, N.C.--(BUSINESS WIRE)--POZEN Inc. (NASDAQ: POZN - News) announced today that John R. Plachetka, Pharm.D., the Company’s Chairman, President and Chief Executive Officer, will present at the Wells Fargo Securities 3rd Annual Healthcare Conference on Wednesday, June 23, 2010 at 10:45 a.m. (ET), at the Intercontinental Hotel in Boston. Dr. Plachetka’s presentation will be webcast and archived on POZEN’s home page at www.pozen.com.
About POZEN
POZEN Inc., headquartered in Chapel Hill, NC, is a pharmaceutical company committed to transforming medicine that transforms lives. Since its founding in 1996, POZEN has successfully created novel pharmacologic agents primarily for pain and pain-related conditions by combining existing drug therapies that result in superior patient outcomes. Moving forward, POZEN is poised to become a model 21st century pharmaceutical company dedicated to ensuring that they produce cost-effective, evidence-based medicines; take a fresh approach to sales, marketing and medical education; and deliver high-quality, affordable pharmaceuticals to their customers. The Company’s common stock is traded on The NASDAQ Stock Market under the symbol “POZN”. For more detailed company information, including copies of this and other press releases, please visit: www.pozen.com.
Contact:
POZEN Inc.
Bill Hodges, 919-913-1030
Chief Financial Officer